A 155% T/O premium as a minimum would equate to roughly $40 per share. I think this is low but would be a starting point for a pre-phase 3 (NNZ-2591) valuation for Neuren. I still think it is absurdly low, but I think it would at least bring some interest back into this stock.
$5B AUD is about $3.32B USD
- This equates to 5B AUD or approx. 3.3B USD
- Less than half of the value of the Reata deal (7.3B USD)
- The lack of Phase 3 success is negated by the price paid for a platform drug that has been shown to be effective in multiple indications
- They also get a share of an approved drug that should grow nicely, and expand into other markets without any investment, included in the price!
Once we have a Phase 3 successfully under our belt, I suspect we would be looking at 15B AUD or roughly 10B USD as a starting point. With current SOI that would equate to $120 per share, ignoring options etc.
Share Price, page-11243
-
- There are more pages in this discussion • 1,545 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.19 |
Change
-0.060(0.49%) |
Mkt cap ! $1.558B | |||
| Open | High | Low | Value | Volume |
| $12.31 | $12.47 | $12.04 | $1.257M | 103.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 1231 | $12.18 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.20 | 4403 | 19 |
View Market Depth
| Last trade - 13.51pm 04/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |